OKYO Pharma (NASDAQ:OKYO - Get Free Report) is expected to post its Q4 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Individuals may visit the the company's upcoming Q4 2026 earning report for the latest details on the call scheduled for Monday, July 20, 2026 at 7:00 AM ET.
OKYO Pharma Stock Down 1.2%
Shares of OKYO stock traded down $0.02 on Monday, reaching $1.66. 4,603 shares of the company were exchanged, compared to its average volume of 166,284. OKYO Pharma has a 1 year low of $1.34 and a 1 year high of $3.35. The business has a 50-day moving average price of $1.58 and a 200 day moving average price of $1.71.
Analyst Upgrades and Downgrades
OKYO has been the topic of several research analyst reports. HC Wainwright lowered their price objective on OKYO Pharma from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Monday, July 13th. Weiss Ratings restated a "sell (d-)" rating on shares of OKYO Pharma in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.67.
View Our Latest Analysis on OKYO
Hedge Funds Weigh In On OKYO Pharma
Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in OKYO Pharma during the fourth quarter worth $36,000. Renaissance Technologies LLC increased its stake in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company's stock worth $286,000 after acquiring an additional 96,800 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of OKYO Pharma during the 3rd quarter worth $31,000. Hedge funds and other institutional investors own 2.97% of the company's stock.
About OKYO Pharma
(
Get Free Report)
Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company's pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.
Okyo Pharma's lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
